Caris Life Sciences, Inc. (NASDAQ: CAI) — Company Overview, News & Financial Data
Caris Life Sciences, Inc.
Caris Life Sciences, Inc.
Caris Life Sciences, Inc. is a precision oncology and molecular diagnostics company that develops and commercializes advanced biotechnology solutions to personalize cancer care. The company performs comprehensive molecular profiling by analyzing DNA, RNA, and proteins using whole exome and whole transcriptome sequencing across tumor tissue and blood samples. Its multi-omic platform generates detailed biomarker data to assist oncologists in treatment selection, risk stratification, and patient monitoring. Additionally, the business maintains a large multimodal database linking genomic profiles with clinical outcomes, providing biopharma partners with data analytics, target discovery, and clinical trial matching services.
Snapshot
Operations
Products and/or services of Caris Life Sciences, Inc.
- Tissue Molecular Profiling: Comprehensive tissue-based molecular profiling analyzes over 23,000 genes via whole exome and whole transcriptomic sequencing from tumor biopsies. The service evaluates DNA, RNA, and protein biomarkers to guide personalized oncological treatment selection and identify therapeutic targets.
- Liquid Biopsy and Blood Profiling: Non-invasive blood-based molecular profiling assays analyze plasma and circulating cellular fractions across the entire genome. These diagnostic tests enable multi-cancer early detection, minimal residual disease monitoring, and therapeutic selection when tissue samples are unavailable or insufficient for analysis.
- Artificial Intelligence Diagnostics: Machine learning algorithms and computational pathology tools evaluate digitized histological slides and molecular data to predict disease recurrence risk, therapy response, and patient outcomes without requiring additional genomic sequencing steps for early-stage cancer management.
- Biopharma Research Services: Specialized commercialization, target discovery, and clinical trial matching services assist pharmaceutical and biotechnology companies. These capabilities integrate molecular insights and clinical research to accelerate the development and patient recruitment for targeted oncology therapeutic candidates.
- Multimodal Health Data: A vast repository combining genomic, transcriptomic, and proteomic data with real-world clinical outcomes from more than 845,000 matched patient cases supports biomedical research, biomarker validation, target identification, and population-level health insights for oncology.
- International Clinical Diagnostics: Proprietary molecular profiling tests and hybrid tissue-and-liquid assays are supplied to healthcare providers globally through specialized international distributors and clinical laboratory partnerships outside the primary domestic market to expand patient access to targeted medicine.
Caris Life Sciences, Inc. executive team
- Dr. David Dean Halbert M.D.Chairman, CEO & Founder
- Mr. Brian J. Brille J.D.Executive Vice Chairman & Executive VP
- Dr. David Spetzler M.B.A., M.S., Ph.D.President
- Mr. Luke PowerSenior VP, CFO & Chief Accounting Officer
- Mr. Jon Mark HarmonSenior VP & Chief Operations Officer
- Dr. Valeriy DomenyukSenior VP & CTO
- Dr. Milan Radovich Ph.D.Senior VP & Chief Scientific Officer
- Ms. Ginger Appleberry J.D.Senior VP, Deputy General Counsel & Chief Compliance Officer
- Mr. J. Russel DentonSenior VP, General Counsel & Secretary
- Mr. Narendra ChokshiSenior Vice President of Corporate Development